Kwanan nan, Nanjing LimingBio's Novel Coronavirus (SARS-CoV-2) antigen gano reagent "StrongStep® SARS-CoV-2 Antigen Rapid Test" ya sami tabbacin aikin Paul-Ehrlich-Institut (PEI *) a Jamus, wannan samfurin ya kasance. wanda Hukumar Kula da Magunguna da Na'urar Lafiya ta Jamus (BfArM) ta tabbatar.LimingBio ya zama ɗaya daga cikin ƴan masana'anta a China waɗanda suka sami takaddun shaida biyu na BfArM+PEI a Jamus.Gwajin sauri na Liming Bio's antigen ya wuce takaddun shaida na Ma'aikatar Lafiya ta ƙasashe da yawa, wanda ke tabbatar da kyakkyawan aikin kit ɗin.
Gwajin saurin antigen na Liming Bio yayi nasarar wuce tabbacin aikin PEI na Jamus
PS PEI: Cibiyar Paul Ehrlich (Jamus: Paul-Ehrlich-Institut), wanda kuma aka sani da Cibiyar Kula da Alurar rigakafi da Biomedicine ta Tarayyar Jamus, cibiyar bincike ce da hukumar kula da lafiya ta Tarayyar Jamus, a halin yanzu a ƙarƙashin Ma'aikatar Lafiya ta Tarayya (BMG). ), yana da aiki mai zaman kansa na binciken samfur na halitta, yarda da gwaji na asibiti, yarda da samfur da tallace-tallace, da ba da tsari.A lokaci guda kuma, tana kuma aiwatar da tsarawa, sake fasalin ƙa'idodin da suka dace, dabayar dasshawarwarin kimiyya ga kungiyoyi daban-daban, musamman wasu kasashen Tarayyar Turai, Tarayyar Turai da kwamitocin kasa da kasa.Al, shibayar dasƙwararrun shawarwari ga gwamnatin Jamus, hukumomin gida da majalisa, da samar da susbayanai masu dacewa ga marasa lafiya da masu amfani.
Gwajin sauri na Liming Bio's antigen cikin nasara ya wuce takardar shedar BfArM ta Jamus
Gwajin sauri na StrongStep® SARS-CoV-2 Antigen Rapid wanda Nanjing Liming Bio ya kirkira ya sami nasarar samun takardar shedar Tarayyar Turai CE, da Cibiyar Kula da Abinci da Magunguna ta kasar Sin (NIFDC) ta tabbatar da rajistar rajista, ta shiga cikin jerin shawarwarin Gidauniyar Rockefeller, da Guatemala. takardar shaida , Takaddun shaida na Ma'aikatar Lafiya ta Italiya, Takaddun shaida na Jamusanci, Takaddun shaida na Ecuador, Takaddun shaida na Brazil (ANVISA), Takaddun shaida na Chile, Takaddun shaida na Argentina, Takaddar Dominica, Takaddun shaida na Guatemala, Takaddun shaida na HSA na Singapore, Malaysia (MDA) takaddun shaida, takaddun shaida na Philippines FDA, takaddar Indonesia, Thailand takardar shaida.Ya sami yabo a cikin kimantawa mai zaman kansa na Ma'aikatar Lafiya da Ayyukan Jama'a ta Burtaniya (DHSC) da (shaidar AAA ta Burtaniya).
Malesiya MDA Novel Coronavirus Antigen Takaddar Gwajin Kai
Features da abũbuwan amfãni
01 Samfurin da ya dace: Tarin samfurin mara lalacewa, miya ko swab na nasopharyngeal.
02 Ganewa da sauri: Duk aikin ganowa yana ɗaukar mintuna 15 kawai, kuma idanu suna lura da sakamakon kai tsaye.
03 Aiki mai sauƙi: Ana iya sarrafa shi ba tare da wani kayan aiki ba kuma ba tare da kwarewa ba.
04 Kyakkyawan aiki: ƙayyadaddun ƙayyadaddun shine 99.26%, hankali shine 96.2%, kuma cikakkiyar daidaito shine 95%.
05 Buƙatar gyare-gyare: A halin yanzu, kamfanin yana da nau'in likitancin ƙwararru, gwajin gida na gida (saliva + nasopharyngeal swab) sigar da sigar gwajin gwaji ta Mini, da dai sauransu. Akwatin marufi da umarni za a iya keɓancewa bisa ga bukatun abokin ciniki.
Wannan Na'urar Na'urar ta SARS-CoV-2 Antigen Rapid Test (nau'in alƙalami) sanye take da na'urar kariya ta ilimin halitta, wacce za ta iya toshe ƙwayar cuta yadda ya kamata a cikin maganin sarrafa samfuran daga juyewa cikin iska, gurɓata muhalli, da kuma kare lafiya yadda ya kamata. ma'aikaci yayin gano gwajin saurin antigen SARS-CoV-2.
Halin da ake ciki a duniya na yanzu yana da tsanani.Tare da bullowa da yaɗuwar bambance-bambancen ƙwayar cuta ta Novel Coronavirus, yanayin annoba a ƙasashe da yankuna da yawa ya sake dawowa, kuma ƙoƙarin rigakafi da shawo kan matsalolin na fuskantar manyan ƙalubale.Gwajin sauri na SARS-CoV-2 Antigen yana da sauri, daidai, mai sauƙin aiki, kuma yana buƙatar ƙananan kayan aiki da ma'aikata.Yana da matukar dacewa da saurin bincike na lamuran da ake zargi da kamuwa da cutar sabon kambi mai girma, kuma yana da tasiri musamman don saurin ganewar cututtukan da aka tattara.Ana iya amfani da shi azaman layin farko na kariya don shawo kan annoba, ana amfani da shi don gano cututtukan da wuri, don taimakawa rigakafi da shawo kan cutar, da sarrafa yaduwar cutar.
Nanjing Liming Bio-products Co., Ltd. an kafa shi a cikin 2001. Kamfanin bincike ne na ilimin halitta wanda ya ƙware a cikin bincike da haɓakawa, samarwa da tallace-tallace na ƙananan ƙwayoyin cuta a cikin vitro diagnostic reagents.Yana da shekaru 20 na kyakkyawan inganci kuma ya tattara cikakken tsarin inganci, kuma ya sami takardar shedar IS013485.Gudanar da samarwa yana gudana daidai da tsarin kula da ingancin ingancin ƙasa, yana tabbatar da cewa samfuran inganci suna hidimar abokan ciniki a duk faɗin duniya.A hankali ya ci gaba da zama sanannen manyan masana'antar fasahar fasahar kere kere ta duniya da ke ƙware a cikin R&D, samarwa, tallace-tallace da sabis na in vitro m diagnostic reagents.
Lokacin aikawa: Oktoba-28-2021
